All In Biotech

Drug Trial Radar · NCT00618202

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions

Last checked: Nov 20, 2026Latest source record: Jan 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

May 2005

Primary completion

Jun 2005

Study completion Jun 2005

Sponsor

Lead sponsor
Roxane LaboratoriesIndustry
Sponsor type
Industry
First posted
Feb 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study was to assess the bioequivalence of a potential generic 750 mg balsalazide disodium capsule formulation compared with Salix Pharmaceutical's 750 mg balsalazide disodium capsule, Colazal, following a single 750 mg dose, administered under fasting conditions.

Conditions

  • Ulcerative Colitis

Interventions

  • BalsalazideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BioequivalenceTime frame: Baseline, Two Period, 7 day washout

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novum Pharmaceutical Research Services

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.